DUNWOODY, Ga., May 7, 2015 /PRNewswire/ -- Myrtle Potter & Company, LLC, a life science and healthcare advisory firm specializing in corporate strategy, product development and product commercialization, today announced the Company has been engaged by Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, to guide and develop the commercialization strategies for the ETC-1002 (bempedoic acid) portfolio.
Founded in 2005 by Myrtle Potter, Myrtle Potter & Company specializes in devising novel strategies to maximize the value of prescription drug brands and portfolios.
“We have a history of working with pharmaceutical and biotech companies to maximize the commercial value of their innovative products,” said Myrtle Potter, CEO. “We are eager to couple Esperion’s lipid-regulating drug development expertise with our commercialization expertise as we work together to successfully commercialize the ETC-1002 portfolio.”
About Myrtle Potter & Company
Myrtle Potter & Company, founded in 2005, is a life science and healthcare advisory firm. Expertise includes business strategy, product commercialization, customer engagement, product development, business development, loss of exclusivity strategies and organization development. With more than 30 years in the healthcare industry, Potter has built an advisory firm that brings proven and relevant experience to their clients.
About Myrtle Potter
Myrtle Potter was president and chief operating officer of Genentech from 2000 to 2005. In this capacity she led the company’s launch of seven products, including the blockbuster cancer therapy Avastin. Prior to that time, Potter was president of Bristol-Myers Squibb’s $4 billion U.S. Cardiovascular and Metabolic business. In this role she led the launch of four drugs, including Plavix, making it the fastest growing prescription drug at that time and setting it on course to be the largest selling pharmaceutical product in the world. Potter also led the commercial efforts for Pravachol (pravastatin) and the Glucophage (metformin) franchise, both multi-billion dollar businesses. Potter began her biopharmaceutical career at Merck and Company where she held positions of increasing responsibility over a period of almost fifteen years. Potter currently serves on the board of directors of several public and private companies.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/myrtle-potter--company-announces-engagement-with-esperion-therapeutics-for-development-of-etc-1002-commercialization-strategy-300079194.html
SOURCE Myrtle Potter & Company, LLC
Help employers find you! Check out all the jobs and post your resume.
